{"entity":{"id":"nct05543330","kind":"trial","name":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","aka":[],"tldr":"A phase 1/2 trial of Cisplatin in non-small-cell lung cancer, run by Wuhan YZY Biopharma Co., Ltd., now recruiting.","summary":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC is a phase 1/2 interventional study registered as NCT05543330 by Wuhan YZY Biopharma Co., Ltd., with 116 participants planned, started 2022-09-30 and due to reach its primary completion in 2026-09-15. Interventions recorded: M701 pleural infusion, Pleural drainage and Cisplatin pleural infusion.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05543330","url":"https://clinicaltrials.gov/study/NCT05543330"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cisplatin"],"companies":["wuhan-yzy-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05543330","phase":"1/2","setting":"A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of M701, a Recombinant Epcam and CD3 Bispecific Antibody , in Patients With Malignant Pleural Effusions Caused by NSCLC","sponsor":"Wuhan YZY Biopharma Co., Ltd.","enrolled":116,"outcomes":[]},"route":"/trials/nct05543330/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"}],"company":[{"id":"wuhan-yzy-biopharma","kind":"company","name":"Wuhan YZY Biopharma","route":"/companies/wuhan-yzy-biopharma/"}]}}